Adc Therapeutics Sa - ADCT STOCK NEWS

ADC Therapeutics (NYSE: ADCT), a biotechnology firm focused on targeted antibody drug conjugates, will host a conference call on March 18, 2021, at 8:30 a.m. ET to discuss its financial results for Q4 and year-end 2020, along with business updates. The lead candidate, loncastuximab tesirine (Lonca), for relapsed large B-cell lymphoma has received priority review by the FDA with a PDUFA date of May 21, 2021. A second candidate, camidanlumab tesirine (Cami), is in a pivotal Phase 2 trial for Hodgkin lymphoma.

ADC Therapeutics SA (NYSE:ADCT), an oncology-focused biotech company, announced that CEO Chris Martin will participate in a fireside chat at the Cowen 41^st Annual Health Care Conference on March 4, 2021, at 12:50 p.m. ET. A live webcast will be available on the company's Investors page, with a replay accessible for 30 days. ADC Therapeutics specializes in antibody drug conjugates for hematological malignancies and solid tumors, leveraging proprietary PBD technology in their clinical pipeline, which includes promising candidates Loncastuximab tesirine and Camidanlumab tesirine.

ADC Therapeutics (NYSE:ADCT) announced the conclusion of enrollment in its pivotal Phase 2 clinical trial for camidanlumab tesirine (Cami) targeting relapsed or refractory Hodgkin lymphoma, with a total of 117 patients enrolled. Preliminary Phase 2 results showed an impressive 83% overall response rate in 47 evaluable patients, maintaining safety profiles from Phase 1. CMC aims to address unmet needs in heavily pre-treated patients and anticipates reporting updated interim data in the first half of the year.

ADC Therapeutics (NYSE:ADCT) has launched an expanded access program (EAP) for loncastuximab tesirine (Lonca), aimed at patients in the U.S. with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This program targets patients who lack treatment options. The FDA is reviewing Lonca's Biologics License Application with a target date of May 21, 2021, for its potential approval. Lonca, an investigational ADC targeting CD19, has shown a promising 48.3% overall response rate in a pivotal Phase 2 trial, exceeding key endpoints.

ADC Therapeutics SA (NYSE:ADCT) announced participation in the SternIR Virtual Corporate Access Event from January 11-14, 2021. The pre-recorded presentation will be available for on-demand viewing starting January 11 at 7:00 a.m. ET and can be accessed through their Investors section for 30 days. ADC Therapeutics focuses on developing antibody drug conjugates (ADCs) for oncology, with lead candidates showing promising clinical results in lymphoma treatments.

ADC Therapeutics (NYSE: ADCT) has entered a joint venture with Overland Pharmaceuticals, forming Overland ADCT BioPharma (CY) Limited. Under this agreement, ADC has licensed exclusive rights for the development and commercialization of four drugs, including Lonca, in Greater China and Singapore. Overland Pharmaceuticals will invest $50 million, acquiring a 51% stake, while ADC retains 49%. This strategic partnership aims to expand access to innovative therapies in oncology and could result in additional milestone payments and royalties for ADC.

ADC Therapeutics (NYSE:ADCT) and Overland Pharmaceuticals have established Overland ADCT BioPharma (CY) Limited to develop four ADC product candidates for hematologic and solid tumors in Greater China and Singapore. Overland Pharmaceuticals has invested $50 million, granting them a 51% stake. ADC Therapeutics retains 49% and can earn milestone payments and royalties. The lead product, Loncastuximab tesirine (Lonca), has shown a 48.3% overall response rate in pivotal trials for relapsed DLBCL. The partnership aims to expand access to innovative therapies in the licensed territories.

ADC Therapeutics (NYSE:ADCT) released updated clinical data for its lead programs, loncastuximab tesirine (Lonca) and camidanlumab tesirine (Cami), at the ASH Annual Meeting. Lonca's pivotal LOTIS 2 trial indicated a 48.3% overall response rate and a 24.8% complete response rate in patients with relapsed or refractory DLBCL. The FDA accepted Lonca's Biologics License Application for priority review, with a PDUFA date of May 21, 2021. Cami's Phase 2 trial showed an 83% overall response rate in Hodgkin lymphoma patients. Both drugs exhibit manageable safety profiles.

ADC Therapeutics SA (NYSE:ADCT) announced a live conference call on December 7, 2020, at 8:00 a.m. ET to showcase presentations at the 62nd ASH Annual Meeting. Key presentations will focus on the lead candidate, loncastuximab tesirine (Lonca), for treating relapsed diffuse large B-cell lymphoma and camidanlumab tesirine (Cami) for Hodgkin lymphoma. Lonca has a 48.3% overall response rate in a Phase 2 trial, while Cami showed an 86.5% response in Phase 1. The call will include insights from expert Mehdi Hamadani, MD, and will be available via webcast.